↓ Skip to main content

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Overview of attention for article published in Journal of Clinical Oncology, November 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
6 news outlets
policy
1 policy source
twitter
28 X users
googleplus
1 Google+ user
guideline
2 clinical guideline sources

Readers on

mendeley
377 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Published in
Journal of Clinical Oncology, November 2016
DOI 10.1200/jco.2016.67.3467
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 28 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 377 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
France 1 <1%
Unknown 376 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 71 19%
Other 56 15%
Student > Bachelor 31 8%
Student > Ph. D. Student 30 8%
Student > Master 23 6%
Other 74 20%
Unknown 92 24%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 171 45%
Biochemistry, Genetics and Molecular Biology 35 9%
Agricultural and Biological Sciences 20 5%
Immunology and Microbiology 16 4%
Pharmacology, Toxicology and Pharmaceutical Science 7 2%
Other 27 7%
Unknown 101 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 73. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 February 2026.
All research outputs
#744,131
of 34,457,357 outputs
Outputs from Journal of Clinical Oncology
#1,741
of 32,389 outputs
Outputs of similar age
#10,394
of 338,033 outputs
Outputs of similar age from Journal of Clinical Oncology
#54
of 271 outputs
Altmetric has tracked 34,457,357 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,389 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,033 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 271 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.